BEIGENE
Founded in 2010, BeiGene is a global biotechnology company that discovers and develops innovative oncology treatments and aims to make their medicines more accessible and affordable to cancer patients worldwide. The company has more than 9,200 colleagues globally and administrative offices on three continents, as well as one of the largest oncology research teams in the world. BeiGene continues to expand its broad in-house internal clinical development capabilities to make its therapies more av... ailable for patients around the globe. BeiGene’s innovative BTK inhibitor BRUKINSA® (zanubrutinib) has been approved in more than 65 markets as a treatment for various blood cancers, and the company's other internally developed cornerstone medicine, tislelizumab, is currently under review by regulators in the U.S. and the EU for the treatment of advanced or metastatic esophageal squamous cell carcinoma after prior chemotherapy. The company’s broad and deep pipeline has the potential to address 80 of cancers by incidence. Adjacent to its product portfolio and pipeline, the company also sponsors programs aimed at serving the broader needs of oncology patients, such as a program to raise awareness of mental health resources for people and families affected by cancer.
BEIGENE
Industry:
Biotechnology Health Care Life Science Medical
Founded:
2010-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.beigene.com
Total Employee:
10001+
Status:
Active
Contact:
+1 (877) 828-5568
Total Funding:
6.79 B USD
Technology used in webpage:
Domain Not Resolving LetsEncrypt Amazon IPv6 ReCAPTCHA Pound Sterling Apple Mobile Web App Capable ASP.NET IIS Microsoft
Similar Organizations
Avadim Health
Avadim Health is a healthcare and wellness company.
Avstera Therapeutics
Avstera Therapeutics is an oncology-focused biotech company that fulfil unmet needs of cancer patients.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Coriell Life Sciences
Coriell Life Sciences delivers the power of precision medicine using pharmacogenomics and clinical decision support software.
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Exuma Biotech
EXUMA Biotech is a clinical-stage biotechnology company that focuses on discovering and developing CAR-T cell products for solid tumors.
IgGenix
IgGenix is a biotechnology company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
Werewolf Therapeutics
Werewolf Therapeutics operates as an oncology biotherapeutics company.
Current Advisors List
Board_member
2013-07-01
Current Employees Featured
Eric Hedrick Chief Advisor @ BeiGene
Chief Advisor
2017-03-01
Jane Huang CMO @ BeiGene
CMO
Anita Wu CCO @ BeiGene
CCO
2019-06-01
John Freeman CSO & SVP @ BeiGene
CSO & SVP
2019-12-01
John V. Oyler CEO & Founder @ BeiGene
CEO & Founder
2010-07-01
Xiaodong Wang Founder & Chairman & Scientific Advisory Board @ BeiGene
Founder & Chairman & Scientific Advisory Board
Shreya Jani VP, Corporate Affairs @ BeiGene
VP, Corporate Affairs
2021-03-01
Michael Schoen CEO & SVP @ BeiGene
CEO & SVP
2017-08-01
Aaron Rosenberg Chief Financial Officer @ BeiGene
Chief Financial Officer
2024-07-01
Rahul Shah Corporate Finance Summer Analyst @ BeiGene
Corporate Finance Summer Analyst
2024-06-01
Founder
Stock Details
Investors List
Hillhouse Investment
Hillhouse Investment investment in Post-IPO Equity - BeiGene
Amgen Ventures
Amgen Ventures investment in Post-IPO Equity - BeiGene
GIC
GIC investment in Post-IPO Equity - BeiGene
Amgen
Amgen investment in Post-IPO Equity - BeiGene
Rock Springs Capital
Rock Springs Capital investment in Series B - BeiGene
Hillhouse Investment
Hillhouse Investment investment in Series B - BeiGene
T. Rowe Price
T. Rowe Price investment in Series B - BeiGene
Hillhouse Investment
Hillhouse Investment investment in Series A - BeiGene
CITIC Capital Holdings
CITIC Capital Holdings investment in Series A - BeiGene
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2024-06-28 | Recorna Bio | BeiGene investment in Seed Round - Recorna Bio | N/A |
| 2023-02-08 | Duo Oncology | BeiGene investment in Seed Round - Duo Oncology | 3 M USD |
| 2021-11-02 | Shoreline Biosciences | BeiGene investment in Series B - Shoreline Biosciences | 140 M USD |
| 2021-06-23 | Strand Therapeutics | BeiGene investment in Series A - Strand Therapeutics | 52 M USD |
| 2021-03-17 | Boston Immune Technologies & Therapeutics | BeiGene investment in Series A - Boston Immune Technologies & Therapeutics | 10 M USD |
| 2020-12-01 | Singlomics | BeiGene investment in Series A - Singlomics | N/A |
| 2020-01-03 | Leap Therapeutics | BeiGene investment in Post-IPO Equity - Leap Therapeutics | 27 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2024-07-18 | BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer |
Official Site Inspections
http://www.beigene.com Semrush global rank: 1.25 M Semrush visits lastest month: 22.27 K
Unable to get host informations!!!
More informations about "BeiGene"
BeiGene - Wikipedia
BeiGene was founded in late 2010 by John V. Oyler, [11] an American entrepreneur who serves as the company's chief executive officer and chairman, [30] alongside Xiaodong Wang, a …See details»
Leadership & Board - BeiGene
Xiaodong Wang, Ph.D. is a co-founder of BeiGene and has served as Chairman of our Scientific Advisory Board since 2011. Dr. Wang has been on the Board of Directors since February …See details»
About Us - Beigene
This is vital as we continue to develop BeiGene in Canada with the goal of bringing innovative, affordable, and accessible treatments to patients and clinicians. Our people are truly our most valuable asset, and creating a …See details»
Our Mission, Vision & Values - BeiGene
Mission. Build the first next-generation oncology company – one that expands the highest quality therapies to more people around the world – through courage, persistent innovation, and challenging the status quo.. Vision. Transform the …See details»
BeiGene Unveils Proposed Name Change to BeOne Medicines, …
Nov 14, 2024 BeiGene, which plans to change its name to BeOne Medicines, is a global oncology company that is discovering and developing innovative treatments that are more …See details»
About Us - BeiMedPlus | Global
At BeiGene, we are passionate about our people, science, and creating a lasting impact. These priorities are of utmost importance to our organization. We strive to build a global organization recognized for its impact in cancer research and …See details»
BeiGene - LinkedIn
BeiGene | 200,016 followers on LinkedIn. Effective March 17, 2025, The U.S. subsidiary of BeiGene, Ltd. has changed its name to BeOne Medicines USA, Inc. This change comes ahead of our anticipated ...See details»
Biotech Leader, BeiGene, Inaugurates Office in Toronto, Canada
May 8, 2024 New Office in Canada Signals BeiGene’s Commitment to Innovating Cancer Care for Canadians. Toronto, May 7, 2024 – BeiGene Canada, the country affiliate of global …See details»
BeiGene - Crunchbase Company Profile & Funding
BeiGene’s innovative BTK inhibitor BRUKINSA® (zanubrutinib) has been approved in more than 65 markets as a treatment for various blood cancers, and the company's other internally developed cornerstone medicine, tislelizumab, …See details»
What We Do - Beigene
BeiGene is focused on creating impactful medicines intended to be accessible to far more patients here in Canada and around the world. We are advancing an innovative, high-value product portfolio primarily targeting blood cancers and …See details»
BeiGene to Present at Upcoming Investor Conferences - Business …
Feb 25, 2025 SAN MATEO, Calif.--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne …See details»
Our Science & Development | BeiGene - BeiGene Nordics
Discover BeiGene's innovative cancer research and development. Learn about our science, global clinical trials, and advancements. Explore more now! ... to cancer biology unites cutting …See details»
Our Science & Medicines - BeiGene Australia
Our Science From the beginning, our Research & Development team has focused on advancing a pipeline that includes potentially first-in-class and best-in-class molecules. We are working toward this goal with one of the largest oncology research teams in the world, and a global clinical development organization that oversees dozens of clinical trials.See details»
Our Mission, Vision & Values | BeiGene - BeiGene Nordics
Explore BeiGene's mission and vision for innovative cancer care. See how our values drive us to create impactful, accessible treatments. Learn more today! Select Your Location: Global; …See details»
BeiGene (Beijing) Co., Ltd. - life-sciences-asia.com
May 31, 2013 BeiGene is a global, commercial-stage, research-based biotechnology company focused on molecularly-targeted and immuno-oncology cancer therapeutics. With a team of …See details»
Diversity, Equity, Inclusion & Belonging - BeiGene
Specific to global gender parity, BeiGene supports the UN’s Women’s Empowerment Principles (WEP) which provides a strong framework to support companies when striving for gender …See details»
BeiGene Global Medical Information Resource Center
BeiGene Global Medical Information addresses medical questions about the use of BeiGene products in patient care with accurate, balanced, and timely clinical and scientific information. …See details»
BeiGene Unveils Proposed Name Change to BeOne Medicines
Nov 15, 2024 All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law. To access …See details»
Our Research and Development | BeiGene - BeiGene Nordics
Inquiries about our Independent Medical Education program and/or the submission process should be directed to the BeiGene Independent Medical Education Administrator at …See details»
BeiGene Announces Closing of Its RMB22.2 Billion (US$3.5 Billion ...
BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.See details»